|
|
|
| Efficacy and safety of Shenqi Fuzheng Injection combined with transcatheter arterial chemoembolization for primary liver cancer：a Meta analysis |
| YANG Wanting HOU Encun |
| The Second Department of Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530011, China |
|
|
|
Abstract Objective To systematically evaluate the efficacy and safety of Shenqi Fuzheng Injection combined with transcatheter arterial chemoembolization (TACE) in the treatment of primary liver cancer. Methods The method of systematic review from the Cochrane library was adopted and clinical controlled trials were retrieved by computer in the Cochrane library, Medline, Embase, PubMed, Wanfang database, Chinese science and technology journal full-text database retrieval (CNKI), China journal full-text database (VIP), etc. "Shenqi Fuzheng Injection", "liver cancer" and "intervention" were used as the keywords to find clinical randomized controlled trials of Shenqi Fuzheng Injection combined with TACE in the treatment of primary liver cancer which were open published from the establishment of database to December 2016. The inclusion and exclusion criteria were used to select the literature by two researchers, the full texts were sought, through quality assessment of literatures and data extraction, finally, the literatures were analyzed statistically by Review Manger 5.2 software eventually. Results There were 7 RCT studies and a total of 466 patients were included. Meta-analysis results showed that compared with single TACE in the treatment of primary hepatocellular carcinoma, the efficiency (RR = 1.45, 95%CI: 1.01-2.07, P = 0.04), the quality of life (RR = 2.29, 95%CI: 1.65-3.17, P ＜ 0.01), CD4+/CD8+ (MD = 0.28, 95%CI: 0.09-0.47, P = 0.003) of Shenqi Fuzheng Injection combined with TACE in the treatment of primary hepatocellular carcinoma were significantly improved, the decrease of white blood cells (RR = 0.68, 95%CI: 0.56-0.83, P = 0.0001) and the occurrence rate of gastrointestinal tract reaction (RR = 0.69, 95%CI: 0.51-0.95, P = 0.02) of which were also lower than TACE. Conclusion Shenqi Fuzheng Injection can improve the efficacy and safety of TACE in the treatment of primary liver cancer.
|
|
|
|
|
|
[1] 郭新忠，戚元刚.超声和CT鉴别诊断肝硬化再生结节和小肝癌的价值分析[J].现代消化及介入诊疗，2015，20（2）：140-142.
[2] 李勃，许晓莲.肝动脉化疗栓塞联合重组人血管内皮抑制素介入治疗原发性肝细胞癌[J].中国肿瘤，2012，21（6）：466-468.
[3] 周滢，周萍.邓中甲教授治疗肝癌经验分析[J].中国实验方剂学杂志，2012，18（2）：260-261.
[4] 石远凯，孙燕.临床肿瘤内科手册[M].北京：人民卫生出版社，2015：132.
[5] 杜同海，祁海平，沈鸿彬，等.参芪扶正注射液辅助治疗肝癌临床疗效观察[J].肿瘤防治研究，2005，32（9）：591-592.
[6] 占国清，李儒贵，谭华炳，等.参芪扶正注射液对中晚期肝癌肝动脉化疗栓塞术后患者生存质量的影响[J].湖北医药学院学报，2013，32（4）：325-328.
[7] 狄灵，杨成志，刘润侠，等.参芪扶正注射液治疗原发性肝癌栓塞化疗综合征的临床研究[J].现代肿瘤医学，2004，12（5）：473-474.
[8] 赵岩.参芪扶正注射液改善肝癌TACE治疗患者生活质量的临床观察[J].光明中医，2016，31（15）：2212-2213.
[9] 黄万里.参芪扶正注射液联合介入治疗原发性肝癌临床研究[J].中国医药指南，2011，9（3）：20-21.
[10] 段方方，覃霄燕，曹旸.参芪扶正注射液配合介入治疗肝癌的临床疗效[J].当代医药论丛，2014，12（3）：304-305.
[11] 张伟，金伟，叶孟，等.参芪扶正注射液对原发性肝癌TACE术后T淋巴细胞亚群的影响[J].医药导报，2009， 28（2）：213-214.
[12] Wong GL，Chan HL，Mak CW，et al. Entecavir treatment reduceshepatic events and deaths in chronic hepatitis B patients with liver cirrhosis [J]. Hepatology，2013，58（5）：1537-1547.
[13] 李焱，程朋.中晚期肝癌临床治疗进展[J].临床肝胆病杂志，2014，30（3）：233-236.
[14] Llovet JM，Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma：chemoembolization improves survival [J]. Hepatology，2003，37（2）：429-442.
[15] 张俊雅，温晓斐，闫鹏，等.原发性肝癌的介入治疗现状与进展[J].现代生物医学进展，2016，54（29）：5797-5800.
[16] 陈子瑶，梁健，邓鑫.中西医结合预防原发性肝癌术后复发作用的系统评价[J].中国中西医结合杂志，2014， 34（6）：671-675.
[17] 程亚茹.102例原发性肝癌患者的TACE治疗及预后影响因素分析[D].济南：山东大学，2016.
[18] 王甦，黄一枫，刘佳，等.TACE治疗原发性肝癌对肝功能的影响及相关因素的研究[J].胃肠病学和肝病学杂志，2016，25（8）：881-884.
[19] Lo CM，Ngan H，Tso WK，et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma [J]. Hepatology，2002， 35（5）：1164-1171.
[20] 饶伟良.介入合并中药治疗肝癌的疗效及并发症观察[J].医学理论与实践，2014，27（1）：63-64.
[21] 苏宏，叶江琳，刘慧，等.参芪化淤方对H22肝癌细胞survivin表达的影响[J].重庆医学，2012，41（25）：2616-2619. |
|
|
|
